Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus DA-EPOCH-R in Aggressive B-Cell Lymphomas
NCT03036904Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Weill Cornell Medicine. Primary endpoints: Maximal Tolerated Dose at 24 months and Dose Limiting Toxicity at 24 months. Started Feb 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)non-Hodgkin lymphoma (NHL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT03036904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036904.